Most Common Side Effects of Ondansetron
The most common adverse effects of ondansetron are headache (occurring in 9-24% of patients), constipation (9%), and diarrhea (4-6%), with these side effects being generally mild and well-tolerated across all clinical settings. 1
Primary Side Effects from Clinical Trials
Gastrointestinal Effects
- Constipation occurs in approximately 9% of patients receiving ondansetron for chemotherapy-induced nausea, compared to less than 1% with placebo 1
- This is the most common side effect when ondansetron is used for IBS-D (irritable bowel syndrome with diarrhea), where it is actually the therapeutic mechanism 2
- Diarrhea paradoxically affects 4-6% of patients, particularly those receiving chemotherapy 1
Neurological Effects
- Headache is the single most frequent adverse effect, reported in 9-24% of patients depending on the clinical setting 1
- In chemotherapy patients receiving 8 mg twice daily, headache occurred in 24% versus 13% with placebo 1
- In postoperative settings, headache affected 9% of patients receiving 16 mg versus 5% with placebo 1
- Malaise/fatigue occurs in 13% of patients, compared to 2% with placebo 1
- Dizziness affects approximately 7% of patients in postoperative settings 1
Other Common Effects
- Fever (pyrexia) occurs in 8% of postoperative patients 1
- Hypoxia is reported in 9% of postoperative patients, though this may be confounded by concurrent perioperative medications 1
Less Common but Clinically Important Side Effects
Hepatic Effects
- Transient elevation of liver enzymes (AST/ALT) occurs in 1-2% of patients receiving ondansetron with chemotherapy 1
- These elevations are typically transient and do not lead to symptomatic hepatic disease 1
- The role of concurrent chemotherapy in these changes makes causality difficult to establish 1
Extrapyramidal Symptoms
- Extrapyramidal reactions occur in less than 1% of patients 1
- This represents a significant safety advantage over metoclopramide, where extrapyramidal symptoms occur in 5% of patients 3
- Rare cases of oculogyric crisis have been reported in postmarketing surveillance 1
Serious but Rare Adverse Effects
Cardiac Effects
- QT interval prolongation can occur, particularly in children with underlying heart disease 4
- Special caution is warranted in patients with congenital long-QT syndrome 5
- Rare cases of arrhythmias (including ventricular and supraventricular tachycardia), bradycardia, and myocardial ischemia have been reported, predominantly with intravenous administration 1
Hypersensitivity Reactions
- Anaphylaxis, bronchospasm, angioedema, and other severe hypersensitivity reactions occur rarely 1
- Laryngospasm, shock, and cardiopulmonary arrest have occurred during allergic reactions to injectable ondansetron 1
Other Rare Effects
- Transient blindness (predominantly with IV administration) has been reported, resolving within minutes to 48 hours 1
- Serotonin syndrome can occur when ondansetron is combined with other serotonergic drugs (SSRIs, SNRIs) 1
Comparative Safety Profile
Ondansetron demonstrates superior tolerability compared to metoclopramide, the previous standard antiemetic 3, 6:
- Adverse events occurred in 45% of ondansetron patients versus 59% with metoclopramide 3
- Diarrhea was less common with ondansetron (15%) than metoclopramide (29%) 3
- Extrapyramidal symptoms occurred in 5% of metoclopramide patients but essentially none with ondansetron 3
Clinical Context Considerations
Pregnancy
- Ondansetron has not been associated with increased risk of stillbirth, spontaneous abortion, or major birth defects 7
- Some studies report possible congenital heart defects when given in the first trimester, so it should be used as second-line therapy before 10 weeks gestation 7
Pediatric Use
- In 209 pediatric patients, the adverse event incidence was only 19%, with headache being most common (4%) 3
- The safety profile in children is generally favorable, though higher weight-based doses may be required 8